This is an archive of papers published by the staff and faculty of Fox Chase Cancer Center. For questions about content, please contact Talbot Research Library
Last updated on
Nejati R , Wei S , Uzzo RG , Poureghbali S , Pei J , Talarchek JN , Ruth K , Dulaimi E , Kutikov A , Testa JR , Al-Saleem T
Monosomy of Chromosome 9 Is Associated With Higher Grade, Advanced Stage, and Adverse Outcome in Clear-cell Renal Cell Carcinoma
Clin Genitourin Cancer. 2020 Feb;18(1) :56-61
PMID: 31648964 PMCID: PMC7781234 URL: https://www.ncbi.nlm.nih.gov/pubmed/31648964
AbstractBACKGROUND: Clear-cell renal cell carcinoma (ccRCC) is one of the most common malignancies in humans and is usually associated with poor outcomes. Cancers are considered to be genetic diseases. Therefore, a better understanding of genetic alterations that are related to disease progression or poor prognosis can help to more precisely identify high-risk patients and treat them more effectively. The aim of this study was to examine the frequency of whole chromosome 9 loss (monosomy of chromosome 9) and its prognostic value in patients with ccRCC. MATERIALS AND METHODS: Single nucleotide polymorphism-based chromosome microarray (CMA) analysis was performed on 103 resected specimens from patients with ccRCC who had undergone partial or radical nephrectomy between January 2002 and March 2017 at Fox Chase Cancer Center. Monosomy 9 was correlated with clinicopathologic parameters and recurrence-free survival. RESULTS: Chromosome 9 loss was detected in 31 (30%) of 103 tumors. Tumors with chromosome 9 loss had higher histologic grade (3 and 4; P < .001) and pathologic stage (P < .001). In 59 patients with non-metastatic ccRCC, chromosome 9 loss was also associated with higher recurrence rate and shorter recurrence-free survival (RFS) (12-month RFS, 77.8%; 95% confidence interval, 36.5%-93.9% for chromosome 9 loss vs. 95.7%; 95% confidence interval, 84.0%-98.9% for no loss; P = .002). CONCLUSIONS: Chromosome 9 loss was found in 30% of patients with ccRCC and correlated with higher grade, advanced stage, and shorter RFS in patients with Stage I to III ccRCC.
Notes1938-0682 Nejati, Reza Wei, Shuanzeng Uzzo, Robert G Poureghbali, Sahar Pei, Jianming Talarchek, Jacqueline N Ruth, Karen Dulaimi, Essel Kutikov, Alexander Testa, Joseph R Al-Saleem, Tahseen Journal Article United States Clin Genitourin Cancer. 2020 Feb;18(1):56-61. doi: 10.1016/j.clgc.2019.09.016. Epub 2019 Sep 26.